Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors – Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – – Median Progression Free...
ARVINAS APPOINTS RONALD PECK, M.D. AS CHIEF MEDICAL OFFICER NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the...
Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy Reimbursement for Company’s non-drug depression treatment, NeuroStar® Advanced Therapy, enables access for depression sufferers in Japan MALVERN, Pa., Aug. 1, 2019 /PRNewswire/...
Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients Enhanced software efficiencies include user-friendly mobile interface and data export to electronic medical records capability MALVERN, Pa., July 29, 2019...
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a...
Kit Check Announces the Latest Bluesight for Controlled Substances Feature, Investigation Portfolios Jenny Harlett July 1, 2019 Workflow collaboration tool helps hospitals locate possible diverters with accuracy Washington DC, June 25, 2019 — Kit Check, the leader in...
Recent Comments